You are here: Industry Insights > Novartis

News List

Novartis granted first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019) Novartis
August 31, 2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.
Novartis’ drug prevents heart attacks and cancer but faces major challenges pharmafile
August 30, 2017
In Novartis’ case, with its drug, canakinumab, it faces major challenges of backing up its data, addressing the safety challenges and addressing the major sticking point of price.
EC approves Novartis’ breast cancer drug Kisqali expressbpd
August 28, 2017
Swiss drugmaker Novartis’ Kisqali (ribociclib) has received approval from the European Commission (EC) as a first-line treatment for advanced breast cancer.
Novartis breast cancer drug Kisqali wins EU approval pharmatimes
August 25, 2017
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Kisqali Receives EU Approval as First-Line Treatment for HR+/HER2- Advanced, Metastatic Breast Cance americanpharmaceuticalreview
August 25, 2017
Novartis announced that the European Commission (EC) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2
Novartis appoints Chief Digital Officer August 25, 2017
Novartis announced that Bertrand Bodson has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis.
Novartis appoints Bertrand Bodson as Chief Digital Officer worldpharmanews
August 25, 2017
Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis.
Novartis receives EU approval for ribociclib europeanpharmaceuticalreview
August 25, 2017
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
Digital-minded Novartis taps Apple's ResearchKit for smartphone MS study fiercepharma
August 24, 2017
Novartis has been quick to embrace sensor technology, launching a Qualcomm smart inhaler collaboration last year.
AmerisourceBergen agrees to $13.4M settlement in Novartis kickback case fiercepharma
August 24, 2017
The specialty pharmacy unit of AmerisourceBergen has agreed to pay more than $13 million to resolve allegations that it got kickbacks to push a drug for Novartis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page